What question did this study set out to answer?

The aim is to identify and evaluate biomarkers for monitoring disease progression in dementia with Lewy bodies (DLB).

Longitudinal biomarkers in dementia with Lewy bodies: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

The aim is to identify and evaluate biomarkers for monitoring disease progression in dementia with Lewy bodies (DLB).
Systematic review and meta-analysis following PRISMA guidelines.
Searched multiple databases for longitudinal studies in DLB with sample size ≥10 and follow-up ≥6 months.
Conducted meta-analysis of three structural MRI studies on whole-brain atrophy.
17 studies included with approximately 460 patients with MCI-LB/DLB.
Structural MRI indicated greater atrophy in DLB + AD compared to DLB and controls (p=0.01).
DAT-SPECT and FDG-PET showed longitudinal changes correlating with clinical progression.

No takes yet. Share an insight, caveat, or question.

Systematic review evaluates biomarkers for tracking progression in dementia with Lewy bodies, suggesting potential for clinical trials.

Alphen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark